NCT06075810View on ClinicalTrials.gov

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

October 31, 2025

Conditions
Breast CancerBreast NeoplasmBreast Cancer Stage IV
Interventions
DRUG

MBQ-167

MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42

Trial Locations (4)

34232

RECRUITING

Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI, Sarasota

37203

RECRUITING

Sarah Cannon Research Institute/SCRI, Nashville

90212

RECRUITING

Precision Next Gen Oncology & Research Center, Beverly Hills

00927

RECRUITING

FDI Clinical Research, San Juan

Sponsors

Lead Sponsor

MBQ Pharma
All Listed Sponsors
collaborator

Congressionally Directed Medical Research Programs

FED

lead

MBQ Pharma

INDUSTRY